EMAIL THIS PAGE TO A FRIEND

Journal of medical genetics

Miglustat as a therapeutic agent: prospects and caveats.


PMID 22892202

Abstract

A viable treatment for lysosomal storage disease has been very difficult to attain. One option is pharmacological inhibition of synthetic pathways to reduce substrate accumulations. Miglustat N-butyldeoxynojirimycin (NBDNJ), an inhibitor of glucosylceramide synthase, has shown much promise in clinical trials for the treatment of Type I Gaucher disease. The molecular events invoked by NBDNJ in cell culture and in animal models have not been so definitive. This review discusses the biochemical and molecular impact of NBDNJ as it relates to its potential as a therapeutic drug.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

D9305
1-Deoxynojirimycin hydrochloride
C6H13NO4 · HCl